Still Struggling With Lobbying Reform

BNA Money and Politics ($$) envisions an intense conflict over lobby reform, warning that a "battle is heating up in the House over disclosure requirements for paid grass-roots lobbying, with opponents criticizing a new proposal (H.R. 2093)." The article describes the outpouring of opposition to the bill (H.R. 2093), which would only require disclosure by grassroots lobbying firms that that receive more than $100,000 a quarter. The bill was introduced so that it could be offered as an amendment if such language is not included in the overall lobbying and ethics bill.

read in full

Sneak Preview: OMB Delays Guidance Documents

By now, we all know President Bush's recent changes to the regulatory process will further bottleneck federal regulatory policy in an attempt to help regulated industries escape new obligations. Specifically, changes regarding agency guidance documents will force those interpretive memos (often only suggestions) through a burdensome and unnecessary White House review process.

read in full

Mixed Signals on Short-Term War Funding Idea

Last month, we reported in Supplemental 2.0 -- Short-Term War Funding? on a legislative strategy proposed by Rep. John Murtha (D-PA), seconded by House Appropriations chair David Obey (D-WI), to approve funding for soldiers only through July, but without any deployment timetables or restrictions in Supp. 1.0. We noted the White House would likely take a dim view of the idea. Indeed it now has; the NYT has WH spokesman Tony Snow saying yesterday that a short-term bill "provides a kind of uncertainty that really is not helpful to commanders."

read in full

Drug Importation Amendment Rendered Impotent

Yesterday, the Senate attached by a voice vote a drug importation amendment to the PDUFA reauthorization/FDA reform bill moving through the chamber. However, the amendment passed with its own amendment (called a second-degree amendment) which requires the Department of Health and Human Services to certify the safety and cost-effectiveness of all imported drugs.

read in full

Economic, Fiscal Round-Up: 1Q07 and 4/07

Some important economic barometers and commentary, mostly pointing to a slowdown in the overall economy, below.
  • L. Josh Bevins, Economic Policy Institute -- GDP growth continues deceleration
  • John Irons, Center for American Progress -- April Job Growth Disappoints
  • CBO -- Federal Fiscal Performance: Monthly Budget Review
  • Bureau of Economic Analysis -- 1Q07 GDP growth factors summarized:

read in full

Forecast for Appropriations Season: Stormy, With a Chance of Oversight

FedTimes on appropriations... Capitol Hill watchers caution agency leaders to expect more hearings, more scrutiny, less predictability and longer wait times for their 2008 budgets. "The one thing that is clear is that departments and agencies are going to be held much more accountable and forced to disclose a lot of information that they haven't previously disclosed, and they are going to be punished if they don't disclose," said Scott Lilly, a senior fellow with the Center for American Progress.

read in full

Post Clarifies Its Supplemental "Concession" Editorial-o

A May 3 Page One article about negotiations between President Bush and congressional Democrats over a war spending bill said the Democrats offered the first major concession by dropping their demand that the bill it include a deadline to bring troops home from Iraq. While Democrats are no longer pushing a firm date for troop withdrawals, party leaders did not specifically make that concession during a Wednesday meeting with Bush at the White House.

read in full

Humble Submission For the CAP-Inclusion Debate

Responding to the new CAP anti-poverty plan, the folks at Inclusionist.org have started up an interesting debate on how to talk about, think about, and address poverty. This post should get you caught up. Call me a kool-aid drinker, but I'm taken in by the Inclusionist people. I like the way they think, perhaps more so than the way they name things. I mean, the term "inclusion" just sounds too social, when we're really talking about pocketbook, security, and opportunity issues. Their work's cut out for them on that front, if they ever want the term and their definition of it to become mainstream.

read in full

I Want My Reg Watch in Review!

Reg•Watch in Review is a biweekly e-newsletter highlighting recent news from the world of regulatory policy. By signing up for Reg•Watch in Review, you will receive convenient updates on White House regulatory policy, scientific integrity, agency rulemakings and much more. (Click here to see the latest issue.) Just fill in your email address and name below, and you will soon receive Reg•Watch in Review in your inbox. Email Address: * First Name: * Last Name: *

read in full

Free Market Follies: The Medicare Advantage Program

Kevin Drum, commenting on a New York Times story about a Medicare program that pays private insurers more per patient than they pay directly to doctors:

read in full

Pages